Clinical trials: Multiple Sclerosis Lesion
Demyelinating Disorders, Multiple Sclerosis
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and a one-time high dose intravenous methotrexate with Leucovorin rescue, along with the standard solumedrol treatment before…
- Conditions
- Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis
- Trial name
- NCT00037115
- Testing
- interferon beta 1a, methotrexate, methylprednisolone
- Where
- United States
- Sponsor
- MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Multiple Sclerosis, RRMS
Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?
The MYTH-MS study is a multicenter prospective study investigating the occurrence of clinical relapses in patients with relapsing-remitting multiple sclerosis (RRMS) in the absence of radiological activity on MRI.
- Conditions
- Multiple Sclerosis, RRMS, Multiple Sclerosis (MS) - Relapsing-remitting
- Trial name
- MYTH-MS (NCT07545889)
- Testing
- Early Cerebro-spinal MRI, Biomarker Assessment, Clinical and Neuropsychological Evaluations
- Where
- 8 sites in France
- Volunteers
- 136 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis
Does Microglial Activation Promote Lesion Growth and Progression Among Multiple Sclerosis Patients
The purpose of this study is to assess whether increased microglial activation (measured using TSPO-PET) at lesion rim is associated with more rapid lesion growth during 10 year follow up.
- Trial name
- FUP-MS (NCT04625049)
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Turku University Hospital
Secondary Progressive Multiple Sclerosis
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
The purpose of this study is to compare expanded disability status scale, annualized relapse rate, Gad-enhanced brain lesions, and side effects after administration of rituximab and glatiramer acetate among patients with active…
- Trial name
- NCT03315923
- Testing
- Rituximab, Glatiramer Acetate
- Where
- Iran
- Volunteers
- 84 people
- Sponsor
- Isfahan University of Medical Sciences
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing…
- Conditions
- Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT02967380
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Southern California
Multiple Sclerosis, Relapsing-Remitting
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose…
- Trial name
- NCT00676715
- Testing
- Ocrelizumab, Avonex
- Where
- 84 sites in United States, Belgium and 16 more
- Volunteers
- 220 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
- Trial name
- NCT00333138
- Testing
- FTY720
- Where
- 26 sites in Canada, Denmark and 9 more
- Volunteers
- 281 people
- Sponsor
- Novartis
Multiple Sclerosis, Multiple Sclerosis Lesion
Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study
The study proposal focuses on multiple sclerosis (MS), a chronic incurable disease of the central nervous system (CNS). The MS disease is characterised by recurrent transient disability progression, quantified by increase in the…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis Lesion, Multiple Sclerosis Brain Lesion
- Trial name
- AI ProMiS (NCT05426980)
- Where
- 4 sites in Slovenia
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- University of Ljubljana
Remitting-Relapsing Multiple Sclerosis
TMP001 in Relapsing-remitting Multiple Sclerosis
The purpose of this study is to assess the impact of TMP001 in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT02686788
- Testing
- TMP001
- Where
- 5 sites in Germany
- Volunteers
- 9 people
- Sponsor
- Dr. Frank Behrens
Multiple Sclerosis, Cognitive Impairment
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients.
- Trial name
- EXCITING (NCT00881205)
- Testing
- Rivastigmine transdermal patch
- Where
- 49 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
This is a randomized, parallel group, placebo-controlled study designed to assess whether GSK239512 can enhance lesion remyelination in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01772199
- Testing
- GSK239512
- Where
- 43 sites in Bulgaria, Canada and 6 more
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a disease of the nervous system. The exact cause of MS is unknown, but it is believed to be an autoimmune condition.
- Trial name
- NCT00001781
- Testing
- CGP 77116
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Lesions, Multiple Sclerosis
Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy
It is difficult to determinate prognostic criteria of Multiple Sclerosis with conventional MRI insofar as physiopathology is not well-known: the precise sequences of events leading to plaque formation and axonal injury are still…
- Trial name
- IRM 3T-SEP (NCT00861172)
- Testing
- 3T MR scanner
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Hospices Civils de Lyon
Multiple Sclerosis
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better.
- Trial name
- NCT06220669
- Testing
- LY3541860
- Where
- 20 sites in United States, France and 5 more
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments.
- Conditions
- Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive
- Trial name
- ReVIVE (NCT05359653)
- Testing
- Clemastine Fumarate
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Exploring Pathology Related to Slowly Expanding Lesions Using Advanced Imaging
This is an open, follow-up study to compare the performance of three critical imaging methods to detect chronic active lesions in Multiple Sclerosis (MS) in vivo.
- Trial name
- SELPET (NCT06460077)
- Where
- Finland
- Volunteers
- 15 people
- Sponsor
- Turku University Hospital
Multiple Sclerosis
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis
This study will determine whether magnetic resonance imaging (MRI) can detect damage to certain parts of the brain and analyze the thickness of the brain's outer surface in patients with multiple sclerosis.
- Trial name
- NCT00099307
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients
This study will determine whether sildenafil citrate, commonly known as Viagra, can cause increased blood flow to the brain in a wide range of multiple sclerosis (MS) patients, including women.
- Trial name
- NCT00094068
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Multiple Sclerosis, Mindfulness
The Effect of a Mindfulness-Based Stress Reduction Program in Patients With Multiple Sclerosis
The aim of this study is to investigate the effect of an mindfulness-based stress reduction (MBSR) program designed in accordance with the literature and the basic principles of the program on fatigue, self-efficacy and stress…
- Conditions
- Multiple Sclerosis, Mindfulness, Upper Motor Neuron Lesion
- Trial name
- NCT06416176
- Testing
- Mindfulness-Based Stress Reduction (MBSR) Program
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Halic University
Multiple Sclerosis, Relapsing-remitting
Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study
To examine short- and long-term value of appearance of new active lesions in predicting extent of cortical and subcortical deep gray matter (SDGM) atrophy over 5 years in ASA (Avonex- Steroid-Azathioprine)study.
- Trial name
- ASA (NCT01628315)
- Testing
- MRI
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- University at Buffalo